SynCore Biotechnology Co Ltd Total Assets
SynCore Biotechnology Co Ltd total assets. Based on the latest financial reports, SynCore Biotechnology Co Ltd (4192) holds total assets worth NT$272.85 Million TWD (≈ $8.60 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 4192 market cap overview for the company's overall valuation and market capitalisation.
Total Assets of SynCore Biotechnology Co Ltd (2015–2024)
Total assets of SynCore Biotechnology Co Ltd from 2015 to 2024. This chart illustrates how SynCore Biotechnology Co Ltd's total assets have evolved over time, based on quarterly financial data. See SynCore Biotechnology Co Ltd (4192) stock price for real-time trading data and today's change.
SynCore Biotechnology Co Ltd - Asset Composition Analysis
SynCore Biotechnology Co Ltd Total Assets Breakdown (December 2024)
SynCore Biotechnology Co Ltd total assets breakdown as of December 2024. SynCore Biotechnology Co Ltd's total assets of NT$272.85 Million consist of 82.0% current assets and 18.0% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 64.7% |
| Accounts Receivable | NT$2.27 Million | 0.7% |
| Inventory | NT$10.05 Million | 3.2% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how SynCore Biotechnology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is SynCore Biotechnology Co Ltd's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SynCore Biotechnology Co Ltd's current assets represent 82.0% of total assets in 2024, an increase from 45.9% in 2015.
- Cash Position: Cash and equivalents constituted 64.7% of total assets in 2024, up from 42.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 29.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 3.2% of total assets.
SynCore Biotechnology Co Ltd Competitors by Total Assets
Key competitors of SynCore Biotechnology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
SynCore Biotechnology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.34 | 15.30 | 2.13 |
| Quick Ratio | 14.73 | 14.86 | 1.68 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$213.31 Million | NT$248.36 Million | NT$393.86 Million |
SynCore Biotechnology Co Ltd - Advanced Valuation Insights
This section examines the relationship between SynCore Biotechnology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.99 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -16.0% |
| Total Assets | NT$317.80 Million |
| Market Capitalization | $18.34 Million USD |
Valuation Analysis
Below Book Valuation: The market values SynCore Biotechnology Co Ltd's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: SynCore Biotechnology Co Ltd's assets decreased by 16.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for SynCore Biotechnology Co Ltd (2015–2024)
The table below shows the annual total assets of SynCore Biotechnology Co Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$317.80 Million ≈ $10.01 Million |
-16.01% |
| 2023-12-31 | NT$378.36 Million ≈ $11.92 Million |
-13.35% |
| 2022-12-31 | NT$436.65 Million ≈ $13.76 Million |
-47.04% |
| 2021-12-31 | NT$824.44 Million ≈ $25.97 Million |
-9.80% |
| 2020-12-31 | NT$913.99 Million ≈ $28.80 Million |
+19.65% |
| 2019-12-31 | NT$763.88 Million ≈ $24.07 Million |
-5.09% |
| 2018-12-31 | NT$804.80 Million ≈ $25.36 Million |
-4.86% |
| 2017-12-31 | NT$845.89 Million ≈ $26.65 Million |
-24.12% |
| 2016-12-31 | NT$1.11 Billion ≈ $35.12 Million |
+8.52% |
| 2015-12-31 | NT$1.03 Billion ≈ $32.36 Million |
-- |
About SynCore Biotechnology Co Ltd
SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the trea… Read more